NTUS Stock Overview
Natus Medical Incorporated provides medical device solutions focuses on the diagnosis and treatment of patients with central nervous and sensory system disorders worldwide.
Natus Medical Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$32.90|
|52 Week High||US$33.93|
|52 Week Low||US$20.90|
|1 Month Change||0.21%|
|3 Month Change||26.83%|
|1 Year Change||25.43%|
|3 Year Change||27.97%|
|5 Year Change||-11.68%|
|Change since IPO||127.68%|
Recent News & Updates
Some Investors May Be Worried About Natus Medical's (NASDAQ:NTUS) Returns On Capital
What underlying fundamental trends can indicate that a company might be in decline? When we see a declining return on...
|NTUS||US Medical Equipment||US Market|
Return vs Industry: NTUS exceeded the US Medical Equipment industry which returned -24% over the past year.
Return vs Market: NTUS exceeded the US Market which returned -18.8% over the past year.
|NTUS Average Weekly Movement||8.8%|
|Medical Equipment Industry Average Movement||10.4%|
|Market Average Movement||8.0%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: NTUS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: NTUS's weekly volatility (9%) has been stable over the past year.
About the Company
Natus Medical Incorporated provides medical device solutions focuses on the diagnosis and treatment of patients with central nervous and sensory system disorders worldwide. It offers products and technologies used for the screening, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological and neurosurgical treatments, epilepsy, sleep disorders, and neuromuscular diseases. The company also provides computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories.
Natus Medical Fundamentals Summary
|NTUS fundamental statistics|
Is NTUS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NTUS income statement (TTM)|
|Cost of Revenue||US$199.61m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||0.37|
|Net Profit Margin||2.65%|
How did NTUS perform over the long term?See historical performance and comparison
Is NTUS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NTUS?
Other financial metrics that can be useful for relative valuation.
|What is NTUS's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does NTUS's PE Ratio compare to its peers?
|NTUS PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
VREX Varex Imaging
LMAT LeMaitre Vascular
MLAB Mesa Laboratories
NTUS Natus Medical
Price-To-Earnings vs Peers: NTUS is good value based on its Price-To-Earnings Ratio (88.8x) compared to the peer average (161.7x).
Price to Earnings Ratio vs Industry
How does NTUS's PE Ratio compare vs other companies in the US Medical Equipment Industry?
Price-To-Earnings vs Industry: NTUS is expensive based on its Price-To-Earnings Ratio (88.8x) compared to the US Medical Equipment industry average (34.5x)
Price to Earnings Ratio vs Fair Ratio
What is NTUS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||88.8x|
|Fair PE Ratio||74.3x|
Price-To-Earnings vs Fair Ratio: NTUS is expensive based on its Price-To-Earnings Ratio (88.8x) compared to the estimated Fair Price-To-Earnings Ratio (74.3x).
Share Price vs Fair Value
What is the Fair Price of NTUS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: NTUS ($32.9) is trading above our estimate of fair value ($19.19)
Significantly Below Fair Value: NTUS is trading above our estimate of fair value.
Price to Earnings Growth Ratio
PEG Ratio: NTUS is poor value based on its PEG Ratio (1.5x)
Discover undervalued companies
How is Natus Medical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NTUS's forecast earnings growth (58.9% per year) is above the savings rate (1.9%).
Earnings vs Market: NTUS's earnings (58.9% per year) are forecast to grow faster than the US market (13.8% per year).
High Growth Earnings: NTUS's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: NTUS's revenue (4.4% per year) is forecast to grow slower than the US market (8.3% per year).
High Growth Revenue: NTUS's revenue (4.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NTUS's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Natus Medical performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NTUS has a large one-off loss of $7.4M impacting its March 31 2022 financial results.
Growing Profit Margin: NTUS became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: NTUS's earnings have grown by 9.7% per year over the past 5 years.
Accelerating Growth: NTUS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: NTUS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).
Return on Equity
High ROE: NTUS's Return on Equity (2.9%) is considered low.
Discover strong past performing companies
How is Natus Medical's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: NTUS's short term assets ($286.8M) exceed its short term liabilities ($112.9M).
Long Term Liabilities: NTUS's short term assets ($286.8M) exceed its long term liabilities ($24.3M).
Debt to Equity History and Analysis
Debt Level: NTUS is debt free.
Reducing Debt: NTUS has no debt compared to 5 years ago when its debt to equity ratio was 35.5%.
Debt Coverage: NTUS has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: NTUS has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies
What is Natus Medical current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NTUS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NTUS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NTUS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NTUS's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as NTUS has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Tom Sullivan (57 yo)
Mr. Thomas Joseph Sullivan, also known as Tom, has been the Chief Executive Officer and President of Natus Medical Incorporated since December 27, 2021 and serves as its Director. Mr. Sullivan served as Pr...
CEO Compensation Analysis
Compensation vs Market: Tom's total compensation ($USD5.17M) is about average for companies of similar size in the US market ($USD4.00M).
Compensation vs Earnings: Tom's compensation has been consistent with company performance over the past year.
Experienced Management: NTUS's management team is considered experienced (3.4 years average tenure).
Experienced Board: NTUS's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Natus Medical Incorporated's employee growth, exchange listings and data sources
- Name: Natus Medical Incorporated
- Ticker: NTUS
- Exchange: NasdaqGS
- Founded: 1987
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$1.134b
- Shares outstanding: 34.24m
- Website: https://www.natus.com
Number of Employees
- Natus Medical Incorporated
- 3150 Pleasant View Road
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/28 00:00|
|End of Day Share Price||2022/06/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.